share_log

Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study For Sorrento Therapeutics On Lymphatic Etanercept Delivery In Rheumatoid Arthritis Patients With Results To Be Presented At The 2022 American College Of Rheumatology Conference

Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study For Sorrento Therapeutics On Lymphatic Etanercept Delivery In Rheumatoid Arthritis Patients With Results To Be Presented At The 2022 American College Of Rheumatology Conference

Nutriband 子公司，4P 治療有限責任公司，對類風濕性關節炎患者的淋巴依那西特淋巴遞送進行 1b 階段臨床研究，結果將在 2022 年美國風濕病學學院會議上展示
Benzinga Real-time News ·  2022/10/26 07:17

Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ:SRNE) with results to be presented at the American College of Rheumatology (ACR) Convergence 2022 Conference on November 13, 2022 as a poster abstract entitled "Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections."

亞洲網加利福尼亞州聖約瑟11月13日電營養帶公司(納斯達克代碼：NTRB)(納斯達克代碼：NTRBW)今天宣佈，其子公司4P治療有限責任公司(以下簡稱4P治療公司)已經為索倫託治療公司(納斯達克：SRNE)進行了一項1b期臨床研究，研究結果將以海報摘要的形式於2022年11月13日在美國風濕病學會會聚2022年會議上公佈，標題為《以淋巴方式遞送依那西普對皮下注射反應不足的患者在標準劑量的50%對類風濕性關節炎的治療效果顯著改善》。

"We are excited about these proof of concept clinical results and the development of Sorrento's Sofusa lymphatic delivery platform for treatment of autoimmune diseases such as rheumatoid arthritis to provide hope for those patients who do not respond adequately to conventional biologic injections," said Alan Smith, Ph.D., President, 4P Therapeutics. "This success highlights the clinical regulatory capabilities of 4P Therapeutics in advancing drug delivery products for our partners."

4P治療公司的艾倫·史密斯博士總裁說：“我們對這些概念驗證臨床結果以及索倫託公司用於治療類風濕性關節炎等自身免疫性疾病的Sofusa淋巴輸送平臺的開發感到興奮，這將為那些對傳統生物注射沒有足夠反應的患者帶來希望。這一成功突顯了4P治療公司在為我們的合作夥伴推進藥物輸送產品方面的臨床管理能力。“

The abstract is available at

摘要可在以下網址查閱

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論